

# Switching between biosimilars


**Under the guidance of a physician, a patient can be switched.**



In stringent regulatory systems, biosimilar medicines are developed to match their respective reference biologic medicines and are approved as having no clinically meaningful differences.



Under the guidance of a physician, a patient can be switched to a biosimilar medicine, back to the reference medicine and, we believe, from one biosimilar medicine to another.



**Sandoz, a Novartis division, supports switching between biosimilars under the guidance of a physician.**